Table 3.
Duration of Follow-Up and Incidence of Regimen Discontinuation Among Individuals Who Switched to DTG/3TC 2DR, Compared Across Strata of Age, Sex, and Race
| Months of Follow-Up | DTG/3TC Discontinuation | |||
|---|---|---|---|---|
| Median (IQR) | n (%) | IR per 100 Person-Years (95% CI) | IRR (95% CI) | |
| Overall, N=787 | 13.6 (8.2, 22.3) | 170 (22) | 17.5 (15.0, 20.3) | NA |
| Age <50 years, N=490 | 13.7 (8.8, 22.2) | 104 (21) | 17.0 (14.0, 20.6) | Reference |
| Age ≥50 years, N=297 | 13.5 (7.5, 22.3) | 66 (22) | 18.2 (14.3, 23.2) | 1.07 (0.79, 1.46) |
| Male sex, N=659 | 13.6 (8.3, 22.4) | 146 (22) | 17.9 (15.2, 21.0) | Reference |
| Female sex, N=128 | 13.6 (7.6, 21.3) | 24 (19) | 15.3 (10.2, 22.8) | 0.85 (0.55, 1.31) |
| Non-Black race, N=537 | 13.3 (7.9, 21.3) | 118 (22) | 17.4 (14.6, 20.9) | Reference |
| Black race, N=250 | 13.3 (7.9, 21.3) | 52 (21) | 17.5 (13.4, 23.0) | 1.00 (0.72, 1.39) |
Note: Incidence rates and incidence rate ratios were estimated using univariate Poisson regression.
Abbreviations: 3TC, lamivudine; CI, confidence interval; DTG, dolutegravir; IQR, interquartile range; IR, incidence rate; IRR, incidence rate ratio; N, number; NA, not applicable.